Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report
Brain metastasis (BM) from colorectal cancer (CRC) is rare and associated with poor prognosis. The mainstay of treatment for BM from CRC is radiotherapy, systemic treatment options for CRC can include novel targeted agents, conventional chemotherapy or a combination of both. Nevertheless, the effica...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-06-01
|
| Series: | CNS Oncology |
| Subjects: | |
| Online Access: | https://www.futuremedicine.com/doi/10.2217/cns-2023-0004 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850152273259266048 |
|---|---|
| author | Ahmad KH Ibrahimi Maysa Al-Hussaini Dima Abu Laban Rula Ammarin Lina Wehbeh Abdelatif Al-Mousa |
| author_facet | Ahmad KH Ibrahimi Maysa Al-Hussaini Dima Abu Laban Rula Ammarin Lina Wehbeh Abdelatif Al-Mousa |
| author_sort | Ahmad KH Ibrahimi |
| collection | DOAJ |
| description | Brain metastasis (BM) from colorectal cancer (CRC) is rare and associated with poor prognosis. The mainstay of treatment for BM from CRC is radiotherapy, systemic treatment options for CRC can include novel targeted agents, conventional chemotherapy or a combination of both. Nevertheless, the efficacy of these systemic treatment options against BM from CRC is not yet fully established. Cetuximab, a monoclonal antibody, has been shown to be effective in patients with KRAS wild-type metastatic CRC. The combination of cetuximab with oxaliplatin-based chemotherapy is commonly utilized as a systemic treatment for metastatic CRC. Hereby, we report a case of BM from CRC with significant response after capecitabine and oxaliplatin (XELOX) combined with cetuximab. |
| format | Article |
| id | doaj-art-03280886fff843bf8d2673b624fcc21c |
| institution | OA Journals |
| issn | 2045-0907 2045-0915 |
| language | English |
| publishDate | 2023-06-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | CNS Oncology |
| spelling | doaj-art-03280886fff843bf8d2673b624fcc21c2025-08-20T02:26:02ZengTaylor & Francis GroupCNS Oncology2045-09072045-09152023-06-0112210.2217/cns-2023-0004Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case reportAhmad KH Ibrahimi0Maysa Al-Hussaini1Dima Abu Laban2Rula Ammarin3Lina Wehbeh4Abdelatif Al-Mousa51Department of Radiation Oncology, King Hussein Cancer Center, Amman, 11941, Jordan2Department of Pathology & Laboratory Medicine, King Hussein Cancer Center, Amman, 11941, Jordan3Department of Radiology, King Hussein Cancer Center, Amman, 11941, Jordan4Department of Internal Medicine, King Hussein Cancer Center, Amman, 11941, Jordan1Department of Radiation Oncology, King Hussein Cancer Center, Amman, 11941, Jordan1Department of Radiation Oncology, King Hussein Cancer Center, Amman, 11941, JordanBrain metastasis (BM) from colorectal cancer (CRC) is rare and associated with poor prognosis. The mainstay of treatment for BM from CRC is radiotherapy, systemic treatment options for CRC can include novel targeted agents, conventional chemotherapy or a combination of both. Nevertheless, the efficacy of these systemic treatment options against BM from CRC is not yet fully established. Cetuximab, a monoclonal antibody, has been shown to be effective in patients with KRAS wild-type metastatic CRC. The combination of cetuximab with oxaliplatin-based chemotherapy is commonly utilized as a systemic treatment for metastatic CRC. Hereby, we report a case of BM from CRC with significant response after capecitabine and oxaliplatin (XELOX) combined with cetuximab.https://www.futuremedicine.com/doi/10.2217/cns-2023-0004brain metastasiscetuximabcolorectal cancertargeted agents |
| spellingShingle | Ahmad KH Ibrahimi Maysa Al-Hussaini Dima Abu Laban Rula Ammarin Lina Wehbeh Abdelatif Al-Mousa Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report CNS Oncology brain metastasis cetuximab colorectal cancer targeted agents |
| title | Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report |
| title_full | Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report |
| title_fullStr | Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report |
| title_full_unstemmed | Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report |
| title_short | Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report |
| title_sort | cetuximab plus xelox show efficacy against brain metastasis from colorectal cancer a case report |
| topic | brain metastasis cetuximab colorectal cancer targeted agents |
| url | https://www.futuremedicine.com/doi/10.2217/cns-2023-0004 |
| work_keys_str_mv | AT ahmadkhibrahimi cetuximabplusxeloxshowefficacyagainstbrainmetastasisfromcolorectalcanceracasereport AT maysaalhussaini cetuximabplusxeloxshowefficacyagainstbrainmetastasisfromcolorectalcanceracasereport AT dimaabulaban cetuximabplusxeloxshowefficacyagainstbrainmetastasisfromcolorectalcanceracasereport AT rulaammarin cetuximabplusxeloxshowefficacyagainstbrainmetastasisfromcolorectalcanceracasereport AT linawehbeh cetuximabplusxeloxshowefficacyagainstbrainmetastasisfromcolorectalcanceracasereport AT abdelatifalmousa cetuximabplusxeloxshowefficacyagainstbrainmetastasisfromcolorectalcanceracasereport |